



## Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference

September 13, 2021

**Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T.**

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced that initial clinical data for RLY-4008 and preclinical data for RLY-2608 have been selected for a plenary oral and poster presentation, respectively, at the upcoming virtual AACR-NCI-EORTC Molecular Targets Conference, being held October 7-10, 2021.

RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2 that entered a first-in-human clinical trial in September 2020. RLY-2608 is the first allosteric, pan-mutant (H1047X, E542X and E545X), and isoform-selective PI3K $\alpha$  inhibitor and is on track to initiate a first-in-human clinical trial in the first half of 2022. Relay Therapeutics will host a live webcast on October 8, 2021 at 12:30 pm E.T. to discuss the results of the two presentations.

### **Late Breaking Plenary Oral Presentation Details for RLY-4008:**

**Title:** First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

**Abstract Number:** LB6604

**Session Title:** Plenary Session 2: New Drugs on the Horizon

**Date/Time:** October 8, 2021 at 10:25 am E.T.

### **Poster Presentation Details for RLY-2608:**

**Title:** Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3K $\alpha$

**Abstract Number:** P251

**Date/Time:** All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021 at 9:00 am E.T.

The presentation and poster will be available shortly after being presented on the Relay Therapeutics website at <https://ir.relaytx.com/news-events/events-presentations>.

### **About RLY-4008**

RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. Preclinically, RLY-4008 demonstrates FGFR2-dependent killing in cancer cell lines and induces regression in in vivo models, while showing minimal inhibition of other targets, including other members of the FGFR family. In addition, RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models. RLY-4008 is currently being evaluated in a first-in-human clinical trial designed to treat patients with advanced or metastatic FGFR2-altered solid tumors. To learn more about the first-in-human clinical trial of RLY-4008, please visit [here](#).

### **About RLY-2608**

RLY-2608 is the lead program of multiple preclinical efforts to discover and develop mutant selective inhibitors of PI3K $\alpha$ . PI3K $\alpha$  is the most frequently mutated kinase in solid tumors, with oncogenic mutations detected in about 13% of patients with solid tumors. Traditionally, the development of PI3K $\alpha$  inhibitors has focused on the active, or orthosteric site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type PI3K $\alpha$  and off-isoform activity. Toxicity related to inhibition of wild-type PI3K $\alpha$  and other PI3K isoforms results in sub-optimal inhibition of mutant PI3K $\alpha$  with reductions in dose intensity and frequent discontinuation. The Dynamo™ platform enabled the discovery of RLY-2608, the first allosteric, pan-mutant (H1047X, E542X and E545X), and isoform-selective PI3K $\alpha$  inhibitor designed to overcome these limitations. RLY-2608 is on path to initiate a first-in-human clinical trial in the first half of 2022.

### **About Relay Therapeutics**

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. The Company's Dynamo™ platform integrates an array of leading-edge computational and experimental approaches to effectively drug protein targets that have previously been intractable. The Company's initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease. For more information, please visit [www.relaytx.com](http://www.relaytx.com) or [follow us on Twitter](#).

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of updates on the clinical development of the programs across Relay Therapeutics' portfolio, including the timing of initiation of a first-in-human clinical trial of RLY-2608, clinical data disclosures of RLY-4008 and preclinical data disclosures of RLY-2608; and potential therapeutic effects of RLY-2608 and RLY-4008. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our clinical trials, strategy and future operations; the delay of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the results of our clinical trials may not be predictive of future results in connection with future clinical trials; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of Relay Therapeutics' planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

**Contact:**

Pete Rahmer  
Senior Vice President, Corporate Affairs and Investor Relations  
617-322-0715  
prahmer@relaytx.com

**Media:**

Dan Budwick  
1AB  
973-271-6085  
dan@1abmedia.com